Everlab raises A$65M Series A to scale preventative healthcare globally

What's the deal? Melbourne healthtech startup Everlab has raised A$65 million in a Series A round led by Airtree VenturesDealroom has a profile for this one. Try Dealroom →, with participation from PluralDealroom has a profile for this one. Try Dealroom →, Left Lane CapitalDealroom has a profile for this one. Try Dealroom →, b2venture, and Australian cricket captain Pat CumminsDealroom has a profile for this one. Try Dealroom →. The company plans to use the funds to expand its preventative healthcare platform internationally.

Founded in 2023, Everlab combines diagnostics, clinicians, specialists, prescriptions, and wearable device data into a single system. It aims to help patients spot health risks earlier and manage long-term care more effectively.

Why now? The raise comes less than a year after Everlab's A$15 million seed round, reflecting rapid growth. The company says it now supports more than 20,000 patients across Australia and New Zealand, has completed over 40,000 consultations, and processes more than 200,000 health reports each month.

Everlab claims it has processed more than 21 million biomarker test results to date, with over 25% of members receiving findings that had not previously been identified. It integrates with more than 1,850 healthcare provider locations and connects with over 30 wearable devices.

What could go wrong? Everlab is betting that patients will trust a single platform with decades of their health data — a significant ask in a sector where privacy concerns run high. Scaling internationally also means navigating different regulatory frameworks and healthcare systems.

"Preventive health has always been service-intensive, and that's exactly what's kept it out of reach for most people," chief executive Marc Hermann said. "Productising it is how we change that."

The signal: Everlab's jump from a A$15 million seed to a A$65 million Series A in under a year — with a transatlantic investor syndicate spanning Airtree Ventures, Left Lane Capital, and b2venture — underscores growing conviction that preventative care platforms can scale like consumer products, not just clinical services. For a company Dealroom classifies as "breakout stage," the pace signals that investors are pricing in a global opportunity, not just an Australian one.

Read more: smartcompany.com.au